From its inception, the U.S. Department of Veterans Affairs has deemed research an essential component to meet its mission: to provide the highest quality of health care possible to those who have served our country. Since 1946, clinical trials have been conducted at the VA that focus on alleviating the conditions prevalent among veterans. The goal of these trials has been to offer new drugs, devices and techniques to veterans to improve their health.
The principal investigators (PI) affiliated with the CRF are VA physicians who are committed to providing excellent care to their patients. Excellent care starts with an informed patient. Though you may receive many benefits from participating in clinical research as a subject–from gaining access to the latest pharmaceutical developments to the empowering feeling of giving back–there can be some risks, so if you are considering the possibility of participating please take time to evaluate for yourself and with your doctor if doing so is an appropriate option.
NOW ENROLLING! Open Clinical Trials:
CONDITIONS
STUDY NAME
MORE
CONTACT
Hypothyroidism
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants (AVANTI)
Anne Marie Webb
502-287-5238
Lung Cancer
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02)
Coordinator
502-287-5222
Colon Cancer
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (AZUR-2)
Coordinator
502-287-5222
Cardiovascular Disease
Veterans Affairs (VA) Lipid Optimization Reimagined (VALOR-QI) in Veterans with Atherosclerotic Cardiovascular Disease (ASCVD) VA Multisite Project (VALOR–QI)
Anne Marie Webb
502-287-5238
Colorectal Neoplasia
Artificial Intelligence for the Management of Colorectal Neoplasia using combined-modality Spectroscopy and Enhanced Imaging – A Multi-Site Study
Anne Marie Webb
502-287-5238
Cognitive Impairment
Cardiovascular Disease
Dementia
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)
Jordan Ricks
502-287-5208
Liver
Liver and Systemic Effects of Toxic Exposures
Jordan Ricks
502-287-5208
Lung Cancer
CliNIcal Utility of ManaGement of Patients witH CT and LDCT Identified Pulmonary Nodules UsinG the Percepta NasAL Swab ClassifiEr (NIGHTINGALE)
Coordinator
502-287-5222
Lung Cancer
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)
Coordinator
502-287-5222
Prostate Cancer
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers (VA-BAT)
Coordinator
502-287-5222
Infectious Disease
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting (RECAP-20)
Coordinator
502-852-1585
Open Clinical Trials (ENROLLMENT CLOSED):
CONDITIONS
STUDY NAME
MORE
CONTACT
Cirrhosis
Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis (SACRED)
Jordan Ricks
502-287-5208
COMING SOON! Clinical Trials (NOT YET ENROLLING):
CONDITIONS
STUDY NAME
MORE
CONTACT
Lung Cancer
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening (PROACT-LUNG)
Coordinator
502-287-5222
Ulcerative Colitis
A Phase 2, Randomized, Double Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and
Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) (SWIFT)
Coordinator
502-287-5238
Ulcerative Colitis
A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy with RO7790121 in Patients with Moderately to Severely Active Ulcerative Colitis (UC) (AMETRINE-1)
Coordinator
502-287-5238
Crohn’s Disease
A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction Therapy with RO7790121 in Patients with Moderately to Severely Active Crohn’s Disease (SIBERITE-2)
Coordinator
502-287-5238
Type I Diabetes
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination with Insulin Aspart, in Adults with Type 1 Diabetes (ONWARDS-11)
Coordinator
502-287-5238
Spinal Cord Injury
ARCIM Therapy To Manage Symptomatic Blood Pressure Instability Secondary To Chronic Spinal Cord Injury (EMPOWER-BP)
Coordinator
502-287-5238
Toxic Exposures
Toxic Exposure Research Program – interventional study for high levels of PFAS
Coordinator
502-287-5238
Toxic Exposures
Military Exposure Research Program – toxic military exposure related liver disease
Coordinator
502-287-5238
Small Cell Lung Cancer
Extensive recurrent small cell lung CA w/ biorepository
Biomarker Directed trial of Temozolomide and PARP
inhibition in relapsed SCLC (Jalal SCLC)
Coordinator
502-287-5238
CLINICAL RESEARCH FOUNDATION INVESTIGATORS
Gastroenterology | Digestive & Liver Health
Endocrinology | Diabetes & Nutrition Care
Infectious Disease
Oncology | Hematology
Gastroenterology | Digestive & Liver Health
Gastroenterology | Digestive & Liver Health
Infectious Disease
Pulmonology
Oncology | Gastroenterology | Digestive & Liver Health
Cardiovascular Medicine
Gastroenterology | Digestive & Liver Health
Endocrinology | Diabetes & Nutrition Care
